A Study to Evaluate MEDI0562 in Combination With Immune Therapeutic Agents in Adult Subjects With Advanced Solid Tumors

NCT ID: NCT02705482

Last Updated: 2019-08-26

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE1
• Total Enrollment: 58 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2016-03-30
• Study Completion Date: 2019-08-07

Brief Summary

The purpose of this study is to evaluate MEDI0562 in combination with immune therapeutic agents in adult subjects with select advanced solid tumors.

Detailed Description

This is a Phase 1 multicenter, open-label study to evaluate the safety, pharmacokinetics, pharmacodynamics, immunogenicity, and antitumor activity of MEDI0562 in combination with immune therapeutic agents in adult subjects with select advanced solid tumors.

Conditions

Select Advanced Solid Tumors

Study Design

• Allocation Method: NON_RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Arm A: MEDI0562 and durvalumab

MEDI0562 and durvalumab

Group Type: EXPERIMENTAL

MEDI0562

Intervention Type: BIOLOGICAL

Subjects will remain on treatment until unacceptable toxicity, documentation of progressive disease (PD), or development of other reason for treatment discontinuation.

Durvalumab

Intervention Type: BIOLOGICAL

Subjects will remain on treatment until unacceptable toxicity, documentation of progressive disease (PD), or development of other reason for treatment discontinuation.

Arm B: MEDI0562 and tremelimumab

MEDI0562 and tremelimumab

Group Type: EXPERIMENTAL

MEDI0562

Intervention Type: BIOLOGICAL

Subjects will remain on treatment until unacceptable toxicity, documentation of progressive disease (PD), or development of other reason for treatment discontinuation.

Tremelimumab

Intervention Type: BIOLOGICAL

Subjects will remain on treatment until unacceptable toxicity, documentation of progressive disease (PD), or development of other reason for treatment discontinuation.

Interventions

MEDI0562

Subjects will remain on treatment until unacceptable toxicity, documentation of progressive disease (PD), or development of other reason for treatment discontinuation.

Intervention Type: BIOLOGICAL

Tremelimumab

Subjects will remain on treatment until unacceptable toxicity, documentation of progressive disease (PD), or development of other reason for treatment discontinuation.

Intervention Type: BIOLOGICAL

Durvalumab

Subjects will remain on treatment until unacceptable toxicity, documentation of progressive disease (PD), or development of other reason for treatment discontinuation.

Intervention Type: BIOLOGICAL

Eligibility Criteria

Inclusion Criteria

Subjects must meet all of the following criteria:

1. Written and signed informed consent.

2. Age ≥ 18 years at the time of study entry.

3. Subjects must have received and have progressed, are refractory, or are intolerant to standard therapy appropriate for the specific tumor type. Subjects should not have received more than 3 prior lines of systemic therapy for recurrent or metastatic.

4. Subjects in the dose-escalation phase, must have histologic documentation of advanced solid tumors, excluding primary CNS tumors and hematologic malignancies.

5. Subjects in the dose-expansion phase, must have recurrent or metastatic disease solid tumors according to treatment arm as specified in the protocol.

6. Subjects who have received prior therapy with regimens containing CTLA 4, PD L1, or PD 1 antagonists are permitted to enroll if additional protocol criteria are met.

7. Subjects must have at least 1 lesion that is measurable using RECIST guidelines.

8. Subjects must consent to provide archived tumor specimens for correlative biomarker studies. In the setting where archival material is unavailable or unsuitable for use, subjects must consent and undergo fresh tumor biopsy.

9. All subjects are encouraged to consent to and provide both pretreatment and on treatment tumor biopsies.

10. ECOG Performance score of 0 or 1, unless protocol exceptions are met.

11. In the opinion of the investigator likely to complete ≥ 8 weeks of treatment.

12. Adequate hematologic, renal and hepatic function as determined by blood laboratory values.

13. At the time of Day 1 of the study, subjects with CNS metastases must have been treated and must be asymptomatic and meet the following:

1. No concurrent treatment, inclusive of, but not limited to surgery, radiation, and/or corticosteroids

2. At least 42 days without progression of CNS metastases as evidenced by magnetic resonance imaging (MRI) or computed tomography (CT) after last day of treatment

3. At least 14 days since last dose of corticosteroids Note: Subjects with leptomeningeal disease or cord compression are excluded from the study.

14. Female subjects of childbearing potential who are sexually active with a non-sterilized male partner must use at least 1 highly effective method of contraception from screening, and must agree to continue using such precautions for 180 days after the final dose of investigational product.

15. Non-sterilized male subjects who are sexually active with a female partner of childbearing potential must use male condom plus, if locally available, spermicide from Day 1 and for 180 days after receipt of the final dose of investigational product.

Exclusion Criteria

Any of the following would exclude the subject from participation in the study:

1. Prior treatment with TNFRSF agonists

2. Prior treatment with IMT for certain disease types may be restricted per protocol.

3. History of severe allergic reactions to any unknown allergens or any components of the study drug formulations

4. Active or prior documented autoimmune disease within the past 2 years.

5. Concurrent enrollment in another clinical study, unless it is an observational clinical study or the follow up period of an interventional study

6. Receipt of any conventional or investigational anticancer therapy not otherwise specified above within 28 days prior to the first dose

7. Any concurrent chemotherapy, IMT, or biologic or hormonal therapy for cancer treatment.

8. Unresolved toxicities from prior anticancer therapy.

9. Systemic therapeutic anticoagulation or daily aspirin dose exceeding 325 mg/per day.

10. Current or prior use of immunosuppressive medication within 14 days prior to the first dose of MEDI0562 with exceptions as per protocol.

11. History of primary immunodeficiency, solid organ transplantation, or tuberculosis

12. Test results indicating active infection with human immunodeficiency virus (HIV) or hepatitis B or C defined by positive serologic testing and confirmatory viral nucleic acid testing

13. Pregnant or breastfeeding women

14. Major surgery within 4 weeks prior to first dose of MEDI0562 or still recovering from prior surgery.

15. Other invasive malignancy within 2 years with the exception of protocol specified criteria

16. Any uncontrolled intercurent illness or condition that, in the opinion of the investigator, would interfere with evaluation of the investigational product or interpretation of subject safety or study results.

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 100 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

MedImmune LLC

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Locations

Research Site

Santa Monica, California, United States

Research Site

Chicago, Illinois, United States

Research Site

St Louis, Missouri, United States

Research Site

Albuquerque, New Mexico, United States

Research Site

New York, New York, United States

Research Site

Huntersville, North Carolina, United States

Research Site

Portland, Oregon, United States

Research Site

Nashville, Tennessee, United States

Research Site

Houston, Texas, United States

Research Site

Villejuif, , France

Research Site

Amsterdam, , Netherlands

Research Site

Amsterdam, , Netherlands

Countries

United States; France; Netherlands

References

Goldman JW, Piha-Paul SA, Curti B, Pedersen KS, Bauer TM, Groenland SL, Carvajal RD, Chhaya V, Kirby G, McGlinchey K, Hammond SA, Streicher K, Townsley DM, Chae YK, Voortman J, Marabelle A, Powderly J. Safety and Tolerability of MEDI0562, an OX40 Agonist mAb, in Combination with Durvalumab or Tremelimumab in Adult Patients with Advanced Solid Tumors. Clin Cancer Res. 2022 Sep 1;28(17):3709-3719. doi: 10.1158/1078-0432.CCR-21-3016.

Reference Type: DERIVED

PMID: 35699623 (View on PubMed)

Other Identifiers

D6060C00002

Identifier Type: -

Identifier Source: org_study_id